- In July 2026, Kate Farms, Inc. reported that its High Protein Nutrition Shake would be available in more than 6,800 Walmart and CVS Health stores nationwide following continued retail expansion and a recent CVS launch.
- Earlier in July, CVS Health also opened new smaller, pharmacy-focused locations, underscoring a push to refine its retail footprint and emphasize in-person pharmacy care across diverse communities.
- Now, we’ll consider how CVS’s rollout of smaller, pharmacy-focused locations could influence its broader investment narrative and future growth positioning.
AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
CVS Health Investment Narrative Recap
To own CVS Health, you need to believe its integrated model of insurance, pharmacy and care delivery can translate into more dependable earnings, despite recent margin pressure and reimbursement headwinds. The rollout of smaller, pharmacy-focused stores supports that narrative around core pharmacy relevance but does not materially change the near term focus on stabilizing medical benefit ratios and managing pharmacy reimbursement risk.
The pharmacy-focused locations announced in July 2026 are most relevant here, because they speak directly to CVS’s effort to keep in-person pharmacy care central while it invests in digital health and value-based care models that underpin its longer term earnings recovery story.
Yet despite these efforts, investors should be aware that persistent pharmacy reimbursement pressure and structurally weak front store trends could still...
Read the full narrative on CVS Health (it's free!)
CVS Health's narrative projects $453.4 billion revenue and $10.7 billion earnings by 2029. This requires 3.8% yearly revenue growth and a $7.8 billion earnings increase from $2.9 billion today.
Uncover how CVS Health's forecasts yield a $111.92 fair value, a 5% upside to its current price.
Exploring Other Perspectives
Five fair value estimates from the Simply Wall St Community span roughly US$104 to almost US$296, showing how far apart individual views on CVS’s worth can be. You can weigh those wide ranging opinions against the risk that ongoing reimbursement pressure and thin margins in key segments may limit how quickly CVS’s integrated model translates into stronger profitability.
Explore 5 other fair value estimates on CVS Health - why the stock might be worth just $104.01!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your CVS Health research is our analysis highlighting 2 key rewards and 5 important warning signs that could impact your investment decision.
- Our free CVS Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CVS Health's overall financial health at a glance.
Ready For A Different Approach?
Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:
- Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
- Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.
- Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com